Treatment Details – 9.0 months

Survival: 9.0 months
   
Toxicity Grade: 2
   
Treatments: Immunotherapy
   
Drugs: Proleukin
Country: United Kingdom
   
City/State/Province: London
   
Hospital: St. Bartholomew’s Hospital
   
Journal: Link
   
Date: 1/2001

Description:
Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy.

Treatment: The treatment consisted of the administration of human recombinant Interleukin-2.

Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains.

Results: Overall median survival was 9 months from the date of first treatment.

Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin).

Correspondence: R.M. Rudd, MD
Navigation